

---

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Rule 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):  
**March 19, 2020**

**CRH MEDICAL CORPORATION**

(Exact name of registrant as specified in its charter)

**British Columbia, Canada**  
(State or other jurisdiction  
of incorporation)

**001-37542**

(Commission File Number)

**Not Applicable**  
(IRS Employer  
Identification No.)

**Suite 578 – 999 Canada Place, World Trade Center, Vancouver,**  
**British Columbia, Canada**  
(Address of principal executive offices)

**V6C 3E1**  
(Zip Code)

**(604) 633-1440**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name of former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**ITEM 7.01****REGULATION FD DISCLOSURE**

On March 19, 2020, CRH Medical Corporation issued a press release regarding changes to its Board of Directors. A copy of the press release is being furnished herewith as Exhibit 99.1.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS****(d) Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Press Release issued by CRH Medical Corporation on March 19, 2020</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

***CRH MEDICAL CORPORATION***

---

(Registrant)

Date: March 19, 2020

By: /s/ Richard Bear

Name: Richard Bear

Title: Chief Financial Officer

## CRH Medical Announces Board Changes

VANCOUVER, March 19, 2020 /CNW/ - **CRH Medical Corporation** (the "**Company**") (TSX: CRH) (NYSE MKT: CRHM), announces that Dr. Anthony Holler has advised the Company that he will resign as a member and Chair of the Board of Directors of the Company effective immediately in order to focus on other business matters.

Dr. Tushar Ramani, CEO of the Company, has been appointed as Chair of the Board and Mr. Ian Webb, an independent director, will act as Lead Director of the Board.

"Tony has made a significant contribution to the Company since joining the Board in 2005," said Dr. Ramani. "On behalf of everyone at CRH Medical and our stakeholders, I thank Tony for his service and wish him the very best in his future endeavors."

### **About CRH Medical Corporation:**

CRH Medical Corporation is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH became a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures in ambulatory surgical centers. To date, CRH has completed 26 anesthesia acquisitions. CRH now serves 58 ambulatory surgical centers in eleven states and performs approximately 378,000 procedures annually. In addition, CRH owns the CRH O'Regan System, a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. CRH distributes the O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves. CRH's O'Regan System is currently used in all 48 lower US states.

View original content:<http://www.prnewswire.com/news-releases/crh-medical-announces-board-changes-301026561.html>

SOURCE CRH Medical Corporation

View original content:

<http://www.newswire.ca/en/releases/archive/March2020/19/c4420.html>

%CIK: 0001461119

**For further information:** please contact: Constantine Davides, CFA, (339) 970-2846, [constantine.davides@westwicke.com](mailto:constantine.davides@westwicke.com), <http://investors.crhsystem.com/>

CO: CRH Medical Corporation

CNW 08:30e 19-MAR-20